We are live on ! Find out more
AYTU icon

AYTU BioPharma

24 hedge funds and large institutions have $4.81M invested in AYTU BioPharma in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.1% less ownership

Funds ownership: 34.4% → 33.31% (-1.1%)

11% less funds holding

Funds holding: 27 → 24 (-3)

19% less capital inflows, than outflows

Capital inflows: $99.1K | Capital outflows: $122K

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
24
Holders Change
-3
Holders Change %
-11.11%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
7
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AYTU Hedge Fund Activity: Q3 2024 in Review

24 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2024, worth a combined $4.81M — down 20% from $5.99M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of AYTU and 0 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was Stonepine Capital Management, adding an estimated $73.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $63.5K sold.

  • 24 institutional investors held AYTU BioPharma (AYTU) as of Q3 2024, down from 27 in Q2 2024.
  • Funds reported $4.81M of AYTU BioPharma stock for Q3 2024, down 20% quarter-over-quarter.
  • 0 funds opened new AYTU BioPharma positions in Q3 2024 and 3 closed out, a net change of -3 holders.
  • The largest AYTU BioPharma buyer in Q3 2024 was Stonepine Capital Management, an estimated $73.8K added.
  • The largest AYTU BioPharma seller in Q3 2024 was Citadel Advisors, an estimated $63.5K sold.

Based on aggregated 13F filings for Q3 2024.